GSK's malaria vaccine sails towards uncharted territory
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline will enter unknown regulatory waters when it eventually comes to seek approval of its paediatric malaria vaccine, RTS,S, the most advanced in development for this disease. The parasite kills more than 800,000 people every year, the majority of whom are children under the age of five in developing countries.